



# What is Partnership in Medication Management (PIMM)?

Purpose:

To examining effects of a partnership in medication management/self-administered medication (PIMM/SAM) program versus standard prescribing practice (SPP) on medication adherence in persons diagnosed with Mood Disorders

# What is PIMM?

- Sequential explanatory mixed-methods study
- Randomized controlled trial plus descriptive phenomenological methods
- 12-month randomized controlled trial
- Poorest outcomes: Purposeful sampling and semi-structured interviews

# Medications in Mood Disorders

- Persons with bipolar disorder or unipolar depression are recommended to continue medication for at least 2 years after the last mood episode to prevent relapse\*\*
- Premature discontinuation of medications is common among patients with mood disorders, but the reasons why this occurs are unclear\*\*

# Reason for PIMM

Administration of medication on inpatient units seldom follows how patients would self-administer medication at home (e.g., time of day; lack of self initiation; use of reminders).

Could this be setting up our Mood Disorders patients to have difficulty managing their medications at home, leading to them prematurely discontinuing their medications?



## PIMM Hypothesis

Helping patients with mood disorders to adhere to their medication preferences and self-guided routines while in the hospital will result in an increase in medication adherence post-discharge.

# Participants

## **Purposeful sample recruited, n=16**

- Persons admitted to St. Joes Mood Disorders Program

### **Inclusion Criteria**

- Dx: Major Depression, Bipolar Disorder, or Dysthymia
- Age 18 and older
- MoCA score  $\geq$  26
- Able to read/write in English

### **Exclusion Criteria**

- cognitive impairment
- brain injuries
- significant suicide risk
- significant homicide risk

# Methods/Procedure

- Screening of Potential Participants
  - MoCA score
  - Diagnosis
  - Risk assessment
  - Physician consultation
- Info about study and Invitation
- Letter of Information and Informed Consent



# Methods/Procedure

- Blind randomization into control group or intervention group
- Un-blinded group allocation
- Initial tools
- Control: standard care
- Intervention: PIMM/SAM Intervention

# PIMM/SAM Intervention

- Individualized 1:1 medication teaching
- Determining and replicating patient preferences
- Choosing reminder strategies
- Patient-led medication administration
- Teach-back method; re-education as needed

# Primary Outcome and Measure

## **Primary Outcome**


Medication adherence

- The Medication Adherence Rating Scale (MARS)

# Secondary Outcomes and Measures

<b>Outcome</b>	<b>Measure</b>
<b>Depression</b>	<b>Beck Depression Inventory (BDI)</b>
<b>Anxiety</b>	<b>Beck Anxiety Inventory (BAI)</b>
<b>Dissociation</b>	<b>Multi-scale Dissociation Inventory (MDI)</b>
<b>Beliefs about medication</b>	<b>Beliefs about Medicines Questionnaires (G-BMQ, SC-BMQ)</b>
<b>Self-efficacy</b>	<b>General Self-efficacy Scale (GSE)</b>
<b>Participant–psychiatrist/therapist relationship</b>	<b>Helping Alliance Questionnaire (HAQ)</b>
<b>Health status</b>	<b>Short Form 36-Health Survey (SF-36)</b>

# What do we think PIMM will do?



Improved self-efficacy in medication management

Improved medication adherence

Decreases in relapse and readmission

Partnership in Medication Management

# FEASIBILITY PILOT RESULTS



# Differences Between Groups

## Baseline

- No statistically significant differences



# Differences Between Groups

## Post-intervention

- Controls held stronger negative beliefs about medications
  - $\mu$ G-BMQ 4.9 points higher (95% CI: 0.8 to 9.0;  $p = 0.041$ )
- Controls scored higher on dissociative symptoms related to depression
  - $\mu$ MDI-DEPR 3.7 points higher (95% CI: -6.7 to -0.8;  $p = 0.033$ )



# Differences Between Groups

## Post-intervention

- Controls rated poorer relationships with their psychiatrist
  - $\mu$ HAQ-PRS 13.8 points lower [95% CI: -28.6 to 1.0;  $p = 0.097$ )
- Controls rated higher anxiety levels
  - $\mu$  BAI 12.7 points higher (95% CI; 0.8 to 24.5;  $p = 0.074$ )

# Differences Between Groups

## Post-intervention

- Controls rated lower general health-related quality-of-life
  - $\mu$ SF-36 general health subscale change score 22.5 points lower (95% CI: -44.4 to 0.06;  $p = 0.076$ )
- MARS not statistically significant

# Moving Forward

- Feasibility: Good!
- Expectation: larger sample size likely to lead to greater significance of results
- Now: Active Recruitment and Data Collection
- Plan:
  - Complete RTC
  - Qualitative investigation
    - Purposeful recruitment of participants with poorest outcomes (MARS <7)

# References

Statistics Canada. (2014). Health trends: Statistics Canada catalogue no. 82-213-XWE. Ottawa. Retrieved from <http://www12.statcan.gc.ca/health-sante/82-213/index.cfm?Lang=ENG>

World Health Organization. (2009). Pharmacological treatment of mental disorders in primary healthcare. Retrieved from [http://apps.who.int/iris/bitstream/10665/44095/1/9789241547697\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/44095/1/9789241547697_eng.pdf?ua=1)

# *Thank you to...*

- Carolina Oremus PI Feasibility Pilot
- Mood Disorders Inpatient Program
  - **Nursing Staff**
  - Psychiatrists, Psychologist, Pharmacist